Yearbook of Oncology | ScienceGate

Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours

Yearbook of Oncology ◽

10.1016/s1040-1741(12)00194-7 ◽

2012 ◽

Vol 2012 ◽

pp. 38-40

Author(s):

R. Theriault

Keyword(s):

Her2 Status ◽

Node Negative ◽

Breast Tumours ◽

Risk Of Recurrence

Download Full-text

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Yearbook of Oncology ◽

10.1016/j.yonc.2012.07.006 ◽

2012 ◽

Vol 2012 ◽

pp. 178-179

Author(s):

A.S. Tsao

Keyword(s):

Single Agent ◽

First Line ◽

Adenocarcinoma Of The Lung ◽

Never Smokers ◽

Gemcitabine And Cisplatin

Download Full-text

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.05.001 ◽

2012 ◽

Vol 2012 ◽

pp. 96-97

Author(s):

C. Lawton

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Watchful Waiting ◽

Early Prostate Cancer

Download Full-text

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.020 ◽

2012 ◽

Vol 2012 ◽

pp. 122-123

Author(s):

J.T. Thigpen

Keyword(s):

Cervical Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Cervical Cancer

Download Full-text

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.029 ◽

2012 ◽

Vol 2012 ◽

pp. 75-76 ◽

Cited By ~ 1

Author(s):

J.T. Thigpen

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Breast Tumors ◽

Her2 Expression ◽

Human Epidermal Growth Factor ◽

Epidermal Growth ◽

Metastatic Sites

Download Full-text

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.001 ◽

2012 ◽

Vol 2012 ◽

pp. 116-117 ◽

Cited By ~ 2

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Multicenter Study ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Efficacy And Safety ◽

Open Label ◽

Polymerase Inhibitor ◽

Brca2 Mutations

Download Full-text

PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

Yearbook of Oncology ◽

10.1016/j.yonc.2012.07.018 ◽

2012 ◽

Vol 2012 ◽

pp. 218-219

Author(s):

R.J. Arceci

Keyword(s):

Molecular Marker ◽

Risk Stratification ◽

Fusion Gene ◽

Gene Status ◽

Current Risk

Download Full-text

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression as a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: the NVALT-4 Study

Yearbook of Oncology ◽

10.1016/j.yonc.2012.06.025 ◽

2012 ◽

Vol 2012 ◽

pp. 194-195

Author(s):

A.S. Tsao

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Cyclooxygenase 2 ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

Yearbook of Oncology ◽

10.1016/j.yonc.2012.06.003 ◽

2012 ◽

Vol 2012 ◽

pp. 176-177

Author(s):

C. Lawton

Keyword(s):

Lung Cancer ◽

Cancer Mortality ◽

Low Dose ◽

Lung Cancer Mortality ◽

Computed Tomographic

Download Full-text

Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis

Yearbook of Oncology ◽

10.1016/j.yonc.2012.07.013 ◽

2012 ◽

Vol 2012 ◽

pp. 213-214

Author(s):

R.J. Arceci

Keyword(s):

Tumor Extension

Download Full-text

Yearbook of Oncology
Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Elsevier

Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression as a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: the NVALT-4 Study

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis

Export Citation Format

Yearbook of OncologyLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Elsevier

Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression as a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: the NVALT-4 Study

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis

Yearbook of Oncology
Latest Publications